Moreover, the combination of these two therapies was more effective in inhibiting tumor growth than either BBR or anti-PD-L1 antibody monotherapy alone (Figure 6B), as quantitatively demonstrated by a calculated Bliss synergy score of +0.0045, indicating synergistic interaction. This evidence concerns the gene CD274 and neoplasm.